WO2008059519A3 - A process for the preparation of intermediates of rosuvastatin - Google Patents

A process for the preparation of intermediates of rosuvastatin Download PDF

Info

Publication number
WO2008059519A3
WO2008059519A3 PCT/IN2007/000441 IN2007000441W WO2008059519A3 WO 2008059519 A3 WO2008059519 A3 WO 2008059519A3 IN 2007000441 W IN2007000441 W IN 2007000441W WO 2008059519 A3 WO2008059519 A3 WO 2008059519A3
Authority
WO
WIPO (PCT)
Prior art keywords
rosuvastatin
preparation
intermediates
conversion
pharmaceutically acceptable
Prior art date
Application number
PCT/IN2007/000441
Other languages
French (fr)
Other versions
WO2008059519A2 (en
Inventor
Narendra Shriram Joshi
Anil Shahaji Khile
Yogesh Baburao Kajale
Hemant Harishchandra Kamble
Original Assignee
Glenmark Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Limited filed Critical Glenmark Pharmaceuticals Limited
Publication of WO2008059519A2 publication Critical patent/WO2008059519A2/en
Publication of WO2008059519A3 publication Critical patent/WO2008059519A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides a process for the preparation of the rosuvastatin intermediates and their conversion to rosuvastatin or its pharmaceutically acceptable salts thereof.
PCT/IN2007/000441 2006-09-25 2007-09-24 A process for the preparation of intermediates of rosuvastatin WO2008059519A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1556/MUM/2006 2006-09-25
IN1556MU2006 2006-09-25

Publications (2)

Publication Number Publication Date
WO2008059519A2 WO2008059519A2 (en) 2008-05-22
WO2008059519A3 true WO2008059519A3 (en) 2009-10-15

Family

ID=39402099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000441 WO2008059519A2 (en) 2006-09-25 2007-09-24 A process for the preparation of intermediates of rosuvastatin

Country Status (1)

Country Link
WO (1) WO2008059519A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
EP2032587A2 (en) 2007-04-18 2009-03-11 Teva Pharmaceutical Industries Ltd. Rosuvastatin intermediates and process for the preparation of rosuvastatin
EP2264015A1 (en) 2009-02-02 2010-12-22 LEK Pharmaceuticals d.d. Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
EP2423195A1 (en) 2010-07-26 2012-02-29 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
CN101955463B (en) * 2010-08-04 2012-01-04 重庆博腾制药科技股份有限公司 Method for preparing rosuvastatin calcium intermediate
CN116217494A (en) * 2022-12-30 2023-06-06 浙江乐普药业股份有限公司 Rosuvastatin intermediate and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0319847A2 (en) * 1987-12-08 1989-06-14 Hoechst Aktiengesellschaft Method for the preparation of optically active 3-desmethylmevalonic acid derivatives and intermediate compounds
US5258544A (en) * 1991-03-05 1993-11-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Synthesis of aldehydes useful in the preparations of HMG-CoA reductase inhibitors
EP0658550A2 (en) * 1993-12-15 1995-06-21 Bristol-Myers Squibb Company Amino acid salts of and methods for preparing antihypercholesterolemic tetrazole compounds
WO2001096347A1 (en) * 2000-06-15 2001-12-20 Bristol-Myers Squibb Company HMG-CoA REDUCTASE INHIBITORS AND METHOD
WO2001096311A2 (en) * 2000-06-15 2001-12-20 Bristol-Myers Squibb Company Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0319847A2 (en) * 1987-12-08 1989-06-14 Hoechst Aktiengesellschaft Method for the preparation of optically active 3-desmethylmevalonic acid derivatives and intermediate compounds
US5258544A (en) * 1991-03-05 1993-11-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Synthesis of aldehydes useful in the preparations of HMG-CoA reductase inhibitors
EP0658550A2 (en) * 1993-12-15 1995-06-21 Bristol-Myers Squibb Company Amino acid salts of and methods for preparing antihypercholesterolemic tetrazole compounds
WO2001096347A1 (en) * 2000-06-15 2001-12-20 Bristol-Myers Squibb Company HMG-CoA REDUCTASE INHIBITORS AND METHOD
WO2001096311A2 (en) * 2000-06-15 2001-12-20 Bristol-Myers Squibb Company Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUDLICKY, M.: "Oxidations in Organic Chemistry. ACS Monograph 186", 1990, AMERICAN CHEMICAL SOCIETY, WASHINGTON DC, pages: 121 - 122 *
PARIKH, J. P. ET AL.: "Sulfur Trioxide in the Oxidation of Alcohols by Dimethyl Sulfoxide.", J. AM. CHEM. SOC., vol. 89, 1967, pages 5505 - 5507 *
TOJO, G. ET AL.: "Oxidation of Alcohols to Aldehydes and Ketones.", 2006, SPRINGER, pages: 97,98, - 121-128 *

Also Published As

Publication number Publication date
WO2008059519A2 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
WO2008130678A3 (en) Rosuvastatin intermediates and process for the preparation of rosuvastatin
WO2009084024A3 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
WO2009036281A3 (en) Bortezomib and process for producing same
WO2008124485A3 (en) Solid forms of pemetrexed
GB0615620D0 (en) A process for the preparation of optically active intermediates
ZA200903533B (en) Process for the preparation of rosuvastatin
WO2007135527A3 (en) Benzimidazolyl compounds
IL180252A0 (en) Intermediates for the preparation of halichondrin b
EP2086945A4 (en) Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2007093627A3 (en) Biocidal composition
WO2010140765A2 (en) Novel method for preparing rosuvastatin, intermediate compounds useful for preparing same, and method for preparing same
WO2009085990A3 (en) Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
WO2008131062A3 (en) Process for preparing capecitabine
WO2009025876A8 (en) Crystalline forms of erlotinib hcl and formulations thereof
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2010129918A8 (en) Triptolide prodrugs
WO2008083130A3 (en) Amorphous and crystalline form a of carvedilol phosphate
WO2009120192A3 (en) Processes for the preparation of benzo-fused dioxin derivatives
HUP0500537A2 (en) Process for the preparation of rosuvastatin via new intermediates
WO2008059519A3 (en) A process for the preparation of intermediates of rosuvastatin
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
WO2008117305A3 (en) A novel process for preparing pregabalin and its acid addition salts
IL184715A0 (en) Process for the preparation of intermediates
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
WO2008049922A3 (en) A new process for the preparation of montelukast

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07866712

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07866712

Country of ref document: EP

Kind code of ref document: A2